The preexposure prophylaxis revolution; From clinical trials to programmatic implementation

Current Opinion in HIV and AIDS

Volumn 11, Issue 1, 2016, Pages 80-86

  Mugo, Nelly R ^a,b,c   Ngure, Kenneth ^c,d   Kiragu, Michael ^e   Irungu, Elizabeth ^a,c   Kilonzo, Nduku ^f  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PARTNERS IN HEALTH   (United States)

^d JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

^e LVCT HEALTH   (Kenya)

^f Evaluation and Research National AIDS Control Council   (Kenya)

Author keywords

HIV prevention; implementation; preexposure prophylaxis; programs

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL EDUCATION; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; PATIENT COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROSTITUTION; REVIEW; SOCIAL MARKETING; AFRICA; CHEMOPROPHYLAXIS; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; FEMALE; HIV INFECTIONS; MALE; ORGANIZATION AND MANAGEMENT; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION; TREATMENT OUTCOME;

AFRICA; ANTI-HIV AGENTS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HEALTH POLICY; HIV INFECTIONS; HUMANS; MALE; PRE-EXPOSURE PROPHYLAXIS; TREATMENT OUTCOME;

EID: 84951905616     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000224     Document Type: Review

References (44)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
2. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083-2090.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
5. Baeten JM, Heffron R, Kidoguchi L, Mugo N, Katabira E, et al. (2015) Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART. CROI. Seattle, Washington.
6. Henderson F, Taylor A, Chirwa L, Williams T, Borkowf C, et al. (2015) Characteristics and oral PrEP adherence in the TDF2 open-label extension in Botswana IAS. Vancouver, Canada.
7. Hosek S, Rudy B, Landovtz B, Kapogiannis BG, Sibbery G, et al. An HIV preexposure prophylaxis (PrEP) demonstration project and safety study for young men who have sex with men in the United States (ATN 110) TUAC0204LB; 2015 19-22 July 2015; Vancouver, Canada.
8. McCormack S, Dunn DT, Desai M, et al. Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2015. S0140-6736(15)00056-2.
9. Molina J-M, Capitant C, Spire B, Pialoux G, Chidiac C, et al. (2015) On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial. CROI. Seattle, Washington.
10. WHO (2015) Guidelines on when to start antiretroviral therapy and preexposure prophylaxis for HIV. www.who. int/hiv/pug/guidelines/earlyreleasearv/en/. [accessed October 8th 2015]
11. Mack N, Wong C, McKenna K, et al. Human resource challenges to integrating HIV pre-exposure prophylaxis (PrEP) into the public health system in Kenya: a qualitative study. Afr J Reprod Health 2015; 19:54-62.
12. Sharma M, Wilton J, Senn H, et al. Preparing for PrEP: perceptions and readiness of canadian physicians for the implementation of HIV preexposure prophylaxis. PLoS One 2014; 9:e105283.
13. Krakower D, Mayer KH. Engaging healthcare providers to implement HIV preexposure prophylaxis. Curr Opin HIV AIDS 2012; 7:593-599.
14. Tripathi A, Ogbuanu C, Monger M, et al. Preexposure prophylaxis for HIV infection: healthcare providers' knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J 2012; 105:199-206.
15. van der Elst EM, Smith AD, Gichuru E, et al. Men who have sex with men sensitivity training reduces homoprejudice and increases knowledge among Kenyan healthcare providers in coastal Kenya. J Int AIDS Soc 2013; 16 (Suppl 3):18748.
16. Ying R, Sharma M, Heffron R, et al. Cost-effectiveness of preexposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. J Int AIDS Soc 2015; 18:20013.
17. National AIDS and STI Control Programme (NASCOP) Kenya AIDS Indicator Survey 2012: Final Report. Nairobi Kenya, NASCOP.
18. Simbayi LC, Shisana O, Rehle T, et al. South African National HIV Prevalence. Incidence and Behaviour Survey 2014; 2012.
19. Tanser F, de Oliveira T, Maheu-Giroux M, Barnighausen T. Concentrated HIV subepidemics in generalized epidemic settings. Curr Opin HIV AIDS 2014; 9:115-125.
20. Seeley J, Nakiyingi-Miiro J, Kamali A, et al. High HIV incidence and sociobehavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda. Sex Transm Dis 2012; 39:433-439.
21. Madise NJ, Ziraba AK, Inungu J, et al. Are slum dwellers at heightened risk of HIV infection than other urban residents? Evidence from population-based HIV prevalence surveys in Kenya. Health Place 2012; 18:1144-1152.
22. Kimani JK, Ettarh R, Ziraba AK, Yatich N. Marital status and risk of HIV infection in slum settlements of Nairobi, Kenya: results from a cross-sectional survey. Afr J Reprod Health 2013; 17:103-113.
23. Kahle EM, Hughes JP, Lingappa JR, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr 2013; 62:339-347.
24. Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabinetenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med 2015; 175:246-254.
25. Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, doubleblind, placebo-controlled trial. Clin Infect Dis 2015; 61:572-580.
26. Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015; 60:1457-1464.
27. Haberer JE, Bangsberg DR, Baeten JM, et al. Defining success with HIV preexposure prophylaxis: a prevention-effective adherence paradigm. AIDS 2015; 29:1277-1285.
28. Bekker L-G, Hughes J, Amico R, Roux S, Hendrix C, et al. (2015) HPTN 067 ADAPT methods and results from women in Cape Town IAS.
29. Idoko J, Folayan MO, Dadem NY, et al. 'Why should I take drugs for your infection?': outcomes of formative research on the use of HIV preexposure prophylaxis in Nigeria. BMC Public Health 2015; 15:349.
30. Corneli A, Perry B, Agot K, et al. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS One 2015; 10:e0125458.
31. van der Straten A, Stadler J, Luecke E, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc 2014; 17:19146.
32. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral preexposure prophylaxis for HIVserodiscordant couples. J Acquir Immune Defic Syndr 2012; 59:463-468.
33. Ngure K, Baeten JM, Mugo N, et al. My intention was a child but I was very afraid: fertility intentions and HIV risk perceptions among HIV-serodiscordant couples experiencing pregnancy in Kenya. AIDS Care 2014; 26:1283-1287.
34. Buchbinder SP, Glidden DV, Liu AY, et al. HIV preexposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis 2014; 14:468-475.
35. Murnane PM, Celum C, Mugo N, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS 2013; 27:2155-2160.
36. Kiwanuka N, Ssetaala A, Nalutaaya A, et al. High incidence of HIV-1 infection in a general population of fishing communities around Lake Victoria, Uganda. PLoS One 2014; 9:e94932.
37. Nel A, Mabude Z, Smit J, et al. HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts. PLoS One 2012; 7:e35278.
38. PriceMA, Rida W, Mwangome M, et al. Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth. J Acquir Immune Defic Syndr 2012; 59:185-193.
39. Kinuthia J, Drake AL, Matemo D, et al. HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. AIDS 2015; 29:2025-2033.
40. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-Analysis. PLoS Med 2014; 11:e1001608.
41. Grant RM, Anderson PL, McMahan V, et al. Uptake of preexposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14:820-829.
42. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014; 66:340-348.
43. Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One 2013; 8:e81997.
44. Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral preexposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis 2013; 13:1021-1028.